Biology and genetics

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Mishima Y et al. Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Dupéré-Richer D et al. Curr Opin Hematol. 2017 Apr 22. doi: 10.1097/MOH.0000000000000358. [Epub ahead of print]. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple…

General

Daratumumab for the treatment of multiple myeloma. Touzeau C et al. Expert Opin Biol Ther. 2017 Apr 24. doi: 10.1080/14712598.2017.1322578. [Epub ahead of print]. New developments in the treatment of multiple myeloma – clinical utility of daratumumab. McEllistrim C et al. Biologics. 2017 Apr 11;11:31-43. doi: 10.2147/BTT.S97633. eCollection 2017. Immunologic approaches for the treatment of multiple myeloma. Rasche L et al. Cancer Treat Rev. 2017 Apr 6;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. [Epub ahead of print]. Which…

Supportive treatments

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Richardson PG et al. Br J Haematol. 2017 Apr 26. doi: 10.1111/bjh.14727. [Epub ahead of print]. Trends in vertebral augmentation for spinal fractures in myeloma patients: a 2002-2012 population-based study using a large national cancer registry. Chokshi FH et al. J Neurointerv Surg. 2017 Apr…

Complications of myeloma and its treatments

Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Lee SE et al. Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000506. [Epub ahead of print]. Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. Law LY et al. Mult Scler Relat Disord. 2017 Apr;13:21-24. doi: 10.1016/j.msard.2017.01.013. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD):…

Current treatments

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print]. Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print]. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation…

IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

Diagnostic tests and prognostic indicators

Diagnostic accuracy of computed tomography-guided biopsy in pathological fractures. Stokes CM et al. ANZ J Surg. 2017 Mar 17. doi: 10.1111/ans.13894. [Epub ahead of print]. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Dutoit JC et al. Skeletal Radiol. 2017 Mar 13. doi: 10.1007/s00256-017-2609-6. [Epub ahead of print]. CXCR4 (CD184) expression on stem cell harvest and…

Related conditions

POEMS Syndrome: an Enigma. Warsame R et al. Curr Hematol Malig Rep. 2017 Mar 15. doi: 10.1007/s11899-017-0367-0. [Epub ahead of print]. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. Ramirez-Alvarado M et al. Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24717. [Epub ahead of print]. The risk of renal disease is increased in…

Emerging treatments

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Shah N et al. Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print]. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Sborov DW et al. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751.…

Biology and genetics

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print]. Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma. Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print]. Identification of…